Harm Reduction and Treatment Approaches for Patients with HCV Using Alcohol

Brenda Bauch APRN, MSN

2/20/24

Presentation Objectives

- Discuss how to talk about alcohol use with patients and connect to resources for treatment or support
- Describe treatment approaches based on a patient's goal of moderating use or abstinence
- Explain efficacy and importance of HCV treatment for patients using alcohol

Disclosure & Conflict of Interest

• I have no disclosures and no conflict of interests

Alcohol Use Disorder

How much does this matter?

- Alcohol consumption is associated with 88,000 US deaths each year
- Due to stigma and shame people may not seek treatment from medical community or elsewhere
- Medications are prescribed to less than 9% of patients who are likely to benefit from them

Alcohol Use Disorder Screening and Diagnosis

- "How many times in the past year have you had 5 (for men) or 4 (for women) or more drinks in a day?" AUDIT-C
- Family history
- DSM 5 Alcohol Use Disorder
 - Impaired control
 - Social impairment
 - Risky use
 - Physical dependence
- History of severe withdrawals or seizures
- Consider pharmacological treatment with moderate to severe disorder (4 or more symptoms from DSM-V)

Alcohol Use Disorder

How much is too much?

- Binge drinking
 - male-5 drinks one occasion
 - Female-4 drinks one occasion
- Heavy alcohol use: Binge drinking on 5 or more days in the past month.





Alcohol Use Disorder

Community and Peer Support

- Peer support groups
 - Minnesota Recovery Connection
 - Alcoholics Anonymous
 - Smart Recovery: Cognitive behavioral practices
 - Refuge Recovery: Buddhist-inspired practices and principles
 - Twin Cities Recovery Project. African American specific resources
 - Bridge Club: Specifically focused on women and LGBTQIA + folks
 - Wilder Foundation. Hmong or Karen language specific resources
 - CLUES. Spanish speaking culture specific
 - Alliance Wellness Center. Somali and East African specific
- Mobil Apps
 - In the room (12-step and non-12 step meetings)
 - Sober grid (recovery coach support)

Naltrexone

- Blocks mu-opioid receptor (long acting naloxone)
 - Decreases impact of positive feedback following alcohol consumption
- Contraindicated for patients taking opioids and with hepatic impairment
- Reduces heavy drinking days as well as total drinks on drinking days
 - Can be used as harm reduction approach
- Side effects include nausea, headache, and dizziness
- Some patients elect to take as needed prior to events with alcohol
- Monitor liver function tests periodically
- Injectable naltrexone can improve adherence

Acamprosate

- Modulates glutamate neurotransmission and decreases cravings
- Second line treatment if naltrexone contraindicated or not effective
- Contraindicated in severe renal disease
- Effective in maintaining abstinence so recommended for patient's who have already obtained sobriety
- Side effects are diarrhea and fatigue

Disulfiram

- Inhibits aldehyde dehydrogenase
- Causes a disulfiram-ethanol reaction if patient's drink alcohol
 - Flushing, sweating, hypotension, vomiting
- Supervised ingestion leads to better outcomes
- Goal of abstinence
- Use cautiously with cardiovascular disease, hx of psychosis, and cirrhotic hepatitis
- Monitor LFTs
- Side effects headache, fatigue, neuropathy

Gabapentin (Off Label)

- Reduced negative affect symptoms that are common during alcohol withdrawal and for the weeks following cessation.
- Some evidence to support that long term use is associated with less return to use of alcohol
- Short prescriptions and close follow up recommended
 - Common dosages would be 300mg TID or 600mg TID
- Effective for mild withdrawals but not effective for preventing seizures or treating moderate to severe withdrawals

Heavy Alcohol Use + HCV = Increased Rates of Cirrhosis





Figure 5. Impact of Alcohol Consumption on HCV Treatment Response

In this study, excessive alcohol consumption was defined as ≥60 g/day for men and ≥40 g/day for women.

Source: Wiley TE, McCarthy M, Breidi L, McCarthy M, Layden TJ. Impact of alcohol on the histological and clinical progression of hepatitis C infection. Hepatology. 1998;28:805-9.

SBIRT Can Work!

- SBIRT: Screening, Brief Intervention, and Referral to Treatment
 - Liver providers were given a 2-h training session regarding SBIRT, as well as National Institute of Alcohol Abuse and Alcoholismdeveloped handouts for SBIRT
- Provider delivered counseling (5-10 min) was correlated with improvement in heavy drinking and abstinence both during and 12 weeks after treatment with DAA therapy



Patel, Y. A., Yao, J., Proeschold-Bell, R. J., Niedzwiecki, D., Goacher, E., & Muir, A. J. (2021). Reduced Alcohol Use Is Sustained in Patients Provided Alcohol-Related Counseling During Direct-Acting Antiviral Therapy for Hepatitis C. *Digestive diseases and sciences*, 66(9), 2956–2963. https://doi.org/10.1007/s10620-020-06616-5

Alcohol Use and Treatment Success with Direct Acting Antiviral Therapy

- Retrospective cohort study (Cartwright et al.) found that there was no difference in rates of negative HCV PCR 12 weeks after treatment for the following:
 - Abstinent without AUD
 - Abstinent with AUD
 - Lower risk consumption of alcohol
 - Moderate risk consumption of alcohol
 - High risk consumption of alcohol or AUD
- Retrospective chart abstraction (Heiman et al.) found no difference in SVR rates or loss to follow-up between various alcohol use indicators.

Supports not withholding treatment for patients with alcohol use and not having abstinence requirements

Cartwright, E. J., Pierret, C., Minassian, C., Esserman, D. A., Tate, J. P., Goetz, M. B., Bhattacharya, D., Fiellin, D. A., Justice, A. C., Lo Re, V., 3rd, & Rentsch, C. T. (2023). Alcohol Use and Sustained Virologic Response to Hepatitis C Virus Direct-Acting Antiviral Therapy. *JAMA network open*, 6(9), e2335715. https://doi.org/10.1001/jamanetworkopen.2023.35715

Heiman, E., Alexander, M., Zhang, R., Zheng, Z., & Miller, L. S. (2024). High Hepatitis C Cure Rates Among Patients With Alcohol Use at a Safety-Net Hepatitis C Clinic. *Journal of addiction medicine*, 10.1097/ADM.00000000001307. Advance online publication.

Thank you!

Questions?

Brenda.bauch@hcmed.org